Compare OneSpan Inc (OSPN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Revvity Inc — how do they compare? OneSpan Inc trades at $15.2 (market cap $571.66M), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc is far larger — about 21.6× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (3.37%). Which is the better fit depends on your goals.
| OSPN | RVTY | |
|---|---|---|
Market Cap | $571.66M | $12.33B |
Sector | Technology | Technology |
52-Week High | $16.32 | $117.75 |
52-Week Low | $10.15 | $82.26 |
Enterprise Value | $529.87M | $14.82B |
Dividend Yield | 3.37% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $15.51, up 0.26% on the day, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and a low P/E of 8.57, indicating potential undervaluation. Recent earnings have consistently beaten expectations, and the company announced a $0.13 dividend for H1 2026. Analyst sentiment is positive with a 66.7% buy rating, though the consensus price target of $13.50 is below the current price.
The outlook for OSPN is cautiously optimistic, supported by solid fundamentals and positive earnings momentum. Key opportunities include attractive valuation and consistent profitability. Risks include negative net cash flow trends and competitive pressures in the cybersecurity sector. Investors should weigh the strong analyst buy sentiment against the below-consensus price target.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
